Կանադա - անգլերեն - Health Canada

teva canada limited - cefoxitin (cefoxitin sodium) - powder for solution - 2g - cefoxitin (cefoxitin sodium) 2g - cephamycins

Կանադա - անգլերեն - Health Canada

teva canada limited - cefoxitin (cefoxitin sodium) - powder for solution - 10g - cefoxitin (cefoxitin sodium) 10g - cephamycins

Կանադա - անգլերեն - Health Canada

pfizer canada ulc - cefoxitin (cefoxitin sodium) - powder for solution - 1g - cefoxitin (cefoxitin sodium) 1g - cephamycins

Կանադա - անգլերեն - Health Canada

pfizer canada ulc - cefoxitin (cefoxitin sodium) - powder for solution - 2g - cefoxitin (cefoxitin sodium) 2g - cephamycins

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

wg critical care, llc - cefoxitin sodium (unii: q68050h03t) (cefoxitin - unii:6oev9dx57y) - treatment cefoxitin for injection, usp is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) lower respiratory tract infections , including pneumonia and lung abscess, caused by streptococcus pneumoniae, other streptococci (excluding enterococci, e.g., enterococcus faecalis [formerly streptococcus faecalis]), staphylococcus aureus (including penicillinase-producing strains), escherichia coli, klebsiella species, haemophilus influenzae, and bacteroides species. (2) urinary tract infections caused by escherichia coli, klebsiella species, proteus mirabilis, morganella morganii, proteus vulgaris and providencia species (including p. rettgeri ). (3) intra-abdominal infections , including peritonitis and intra-abdominal abscess, caused by escherichia coli, klebsiella species, bacteroides species including bacteroides fragilis, and clostridium species. (4) gynecological infections , including endometritis,

Միացյալ Թագավորություն - անգլերեն - MHRA (Medicines & Healthcare Products Regulatory Agency)

milpharm ltd - pivmecillinam hydrochloride - oral tablet - 200mg

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

wockhardt limited - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 125 mg - cefuroxime axetil tablets, usp are indicated for the treatment of adult patients and pediatric patients (13 years and older) with mild-to-moderate pharyngitis/tonsillitis caused by susceptible strains of streptococcus pyogenes . limitations of use - the efficacy of cefuroxime axetil tablets, usp in the prevention of rheumatic fever was not established in clinical trials. - the efficacy of cefuroxime axetil tablets, usp in the treatment of penicillin-resistant strains of streptococcus pyogenes has not been demonstrated in clinical trials. cefuroxime axetil tablets, usp are indicated for the treatment of pediatric patients (who can swallow tablets whole) with acute bacterial otitis media caused by susceptible strains of streptococcus  pneumoniae , haemophilus influenzae (including β- lactamase-producing strains), moraxella catarrhalis (including β- lactamase-producing strains), or streptococcus pyogenes. cefuroxime axetil tablets, usp are indicated for the treatment of adu

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime axetil tablets, usp are indicated for the treatment of adult patients and pediatric patients (13 years and older) with mild-to-moderate pharyngitis/tonsillitis caused by susceptible strains of streptococcus pyogenes . limitations of use - the efficacy of cefuroxime axetil tablets, usp in the prevention of rheumatic fever was not established in clinical trials. - the efficacy of cefuroxime axetil tablets, usp in the treatment of penicillin-resistant strains of streptococcus pyogenes has not been demonstrated in clinical trials. cefuroxime axetil tablets, usp are indicated for the treatment of pediatric patients (who can swallow tablets whole) with acute bacterial otitis media caused by susceptible strains of streptococcus   pneumoniae , haemophilus influenzae (including β - lactamase-producing strains), moraxella catarrhalis (including β - lac

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - probenecid 500mg;  ;  ;  ;  ; probenecid 500mg; probenecid 500mg - film coated tablet - 500 mg - active: probenecid 500mg         excipient: colloidal silicon dioxide magnesium stearate maize starch microcrystalline cellulose opadry clear ys-1-7006 opadry yellow ys-1-2063 povidone sodium starch glycolate stearic acid active: probenecid 500mg excipient: colloidal silicon dioxide magnesium stearate maize starch microcrystalline cellulose opadry clear ys-1-7006 opadry yellow ys-1-2063 povidone sodium starch glycolate stearic acid active: probenecid 500mg excipient: colloidal silicon dioxide magnesium stearate maize starch microcrystalline cellulose opadry clear ys-1-7006 opadry yellow ys-1-2063 povidone sodium starch glycolate stearic acid - · probenecid is a uricosuric agent for the treatment of hyperuricaemia in all stages of gout and gouty arthritis except a presenting acute attack. asymptomatic hyperuricaemia seems to occur in a significant percentage of relatives of gouty patients. probenecid may be given prophylactically to these people to forestall gouty attacks and urate deposition in tissues. by virtue of its effective uricosuric activity, probenecid may be used to control the hyperuricaemia induced or aggravated by many diuretics employed for the treatment of oedema and hypertension (e.g. thiazides and similar diuretics).

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

apotex corporation - cefoxitin sodium (unii: q68050h03t) (cefoxitin - unii:6oev9dx57y) - many infections caused by aerobic and anaerobic gram-negative bacteria resistant to some cephalosporins respond to cefoxitin. similarly, many infections caused by aerobic and anaerobic bacteria resistant to some penicillin antibiotics (ampicillin, carbenicillin, penicillin g) respond to treatment with cefoxitin. many infections caused by mixtures of susceptible aerobic and anaerobic bacteria respond to treatment with cefoxitin. cefoxitin for injection is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) lower respiratory tract infections , including pneumonia and lung abscess, caused by streptococcus pneumoniae , other streptococci (excluding enterococci, e.g., enterococcus faecalis [formerly streptococcus faecalis ]), staphylococcus aureus (including penicillinase-producing strains), escherichia coli, klebsiella species, haemophilus influenzae, and bacteroides species. (2) urinary tract infections caused by